IGR_CAP1_DOCETAXEL_GE_STUDY_NN

ABSTRACT: Docetaxel is used as a standard treatment in patients with metastatic castration-resistant prostate cancer. However, a large subset of patients develops resistance by mechanisms that remain largely unknown. It is thus important to define the relevant pathways implicated in docetaxel-resistance and validate predictive biomarkers that will allow approaches of personalized treatment. In this aim, we established resistant IGR-CaP1 prostate cancer cell lines to different doses of docetaxel (IGR-CaP1-R cell lines) and investigated gene expression profiles by microarray analyses. We generated a signature of 112 genes potentially implicated in docetaxel-resistance whose expression is highly modified (Fold change M-bM-^IM-% 5). Among these genes, significant modification of expression was observed

ORGANISM(S): Homo sapiens

SUBMITTER: Philippe DESSEN 

PROVIDER: E-MTAB-1221 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress